EGFR TKIs have been recommended as a potential first‐line treatment for advanced NSCLC patients with somatic EGFR TK domain mutations such as exon 19 deletions (E746‐A750 (2235‐2249del), E746‐A750 (2236‐2250del), L747‐E749 A750P (2239–2247 and 2248del), etc.), and a exon 21 point mutation (L858R).3, 16, 17. Here, EGFR is linked to non-small cell lung carcinoma.